News
-
-
-
COMMUNIQUÉ DE PRESSE
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health, Inc. provides promising results on crofelemer for pediatric intestinal failure patients at ESPGHAN Meeting. Liquid oral crofelemer shows significant reductions in parenteral support requirements normalized to body weight -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Jaguar Health, Inc. continues global development program for crofelemer in pediatric intestinal failure patients with MVID and SBS-IF. Special Stock Dividend and conversion of Preferred Stock announced to benefit stockholders -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar submits NADA for Canalevia-CA1 to FDA for CID in dogs, reporting positive results in study. Crofelemer effectively treats chemotherapy-induced diarrhea -
